Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR

Key Terms

spatial proteomics medical

Spatial proteomics maps which proteins are present and exactly where they sit within cells and tissues, combining a protein “inventory” with a location map. For investors it matters because knowing the physical location of disease-related proteins helps identify better drug targets, improves diagnostic markers and reduces the risk of costly late-stage failures — like a city map that shows both who is working and where they are so planners can make smarter choices.

translational research medical

Translational research turns laboratory discoveries into tests, treatments, or medical products for people, acting as the bridge between basic science and practical use. Like converting a prototype into a store-ready product, it shows whether promising biology can become a safe, regulated, and sellable therapy, diagnostic, or device. For investors, clear translational progress reduces technical and regulatory uncertainty, creates milestone-driven value, and signals when commercial returns might be possible.

biomarkers medical

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

spatial-omics medical

Spatial-omics is a group of laboratory methods that create detailed maps showing which molecules (like RNA or proteins) are present and exactly where they are located inside tissue or cells. For investors, these maps can speed and sharpen drug discovery, diagnostics and patient selection by revealing how diseases work at the neighborhood level within tissue—like turning a grocery list into a kitchen map that shows not just ingredients but where and how they’re used.

AI-informed technical

A decision, analysis or piece of content described as “ai-informed” is one where artificial intelligence tools have contributed insights or data but a human has shaped, verified or made the final call. For investors, this signals faster processing of large datasets and potentially deeper pattern detection, while also highlighting the need to check for model errors, bias and explainability—like using a calculator to speed computations but still reviewing the results.

solid tumor medical

A solid tumor is a localized mass of abnormal cells that forms in an organ or tissue, like a lump in the lung, liver or breast, as opposed to cancers that circulate in the blood. For investors it matters because solid tumors determine how treatments are developed, tested and approved — like choosing tools for a visible fortress versus scattered targets — affecting trial design, potential market size and regulatory risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The new platform delivers unmatched quantitation, robustness, and throughput to support clinical translation of spatial proteomics assays

ORLANDO, Fla.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical applications.

As spatial proteomics moves from discovery to translational research and to diagnostic development, researchers face increasing demands for assay reproducibility, standardization, quantitative confidence, and throughput across large clinical cohorts. CellScape XR incorporates advances in optics, fluidics, and protocols to specifically meet these needs, combining highly multiplexed protein detection with improved throughput and workflow flexibility, without compromising spatial resolution or data quality.

Additionally, Bruker has supported collaborations to advance translational spatial biology on the CellScape platform, including at the University Hospital Schleswig-Holstein, Kiel (UKSH). UKSH has completed analysis of more than 1000 clinically annotated samples with plans to extend the study to approximately 3,000 patient samples.

“We are deploying the CellScape platform to develop translational predictive and prognostic spatial-omics panels and AI-informed signatures across multiple solid tumor indications,” said Niclas C. Blessin MD, Assistant Professor of Pathology at UKSH. “The quantitative consistency and throughput of the CellScape platform allows us to evaluate spatially resolved biomarkers across large patient cohorts, which is essential for building clinically meaningful prognostic assays. Our long-term goal is to translate this work to the clinic, and CellScape XR provides the technical foundation to get there.”

With the launch of CellScape XR, Bruker reinforces its commitment to supporting the full lifecycle of spatial proteomics—from discovery research to translational research to clinical assay development. By enabling scalable, quantitative spatial analysis, CellScape XR is poised to accelerate the development of next-generation diagnostics and prognostics that capture the spatial complexity of disease biology.

Join Bruker at AGBT 2026

Bruker will share more details on the next-generation CellScape XR, alongside innovations across the broader Bruker Spatial Biology portfolio, at the AGBT hospitality suite in Dade Lounge throughout the week and in their Silver Sponsor Workshop on Wednesday, February 25.

For more information, please visit www.brukerspatialbiology.com.

About Bruker Corporation – Leader of the Post-Genomic Era

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260225450411/en/

Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Media Contact:
Johnny Lyssand, PhD
Senior Director, Downstream Marketing
Bruker Spatial Biology
T: +1 (206) 790-2843
E: john.lyssand@bruker.com

Source: Bruker Corporation